vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Summit Midstream Corp (SMC). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $142.3M, roughly 1.4× Summit Midstream Corp). Summit Midstream Corp runs the higher net margin — -5.1% vs -14.6%, a 9.4% gap on every dollar of revenue. Summit Midstream Corp produced more free cash flow last quarter ($34.5M vs $-18.7M).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Summit Midstream Corp is a North American midstream energy firm serving upstream oil and gas producers. It runs natural gas and crude gathering pipelines, compression facilities, and produced water handling services, with assets across key US onshore resource basins.

AXSM vs SMC — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.4× larger
AXSM
$196.0M
$142.3M
SMC
Higher net margin
SMC
SMC
9.4% more per $
SMC
-5.1%
-14.6%
AXSM
More free cash flow
SMC
SMC
$53.3M more FCF
SMC
$34.5M
$-18.7M
AXSM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
SMC
SMC
Revenue
$196.0M
$142.3M
Net Profit
$-28.6M
$-7.3M
Gross Margin
72.1%
Operating Margin
-13.8%
-5.5%
Net Margin
-14.6%
-5.1%
Revenue YoY
65.0%
Net Profit YoY
61.9%
EPS (diluted)
$-0.55
$-0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
SMC
SMC
Q4 25
$196.0M
$142.3M
Q3 25
$171.0M
$146.9M
Q2 25
$150.0M
$140.2M
Q1 25
$121.5M
$132.7M
Q4 24
$118.8M
Q3 24
$104.8M
$102.4M
Q2 24
$87.2M
Q1 24
$75.0M
Net Profit
AXSM
AXSM
SMC
SMC
Q4 25
$-28.6M
$-7.3M
Q3 25
$-47.2M
$-1.6M
Q2 25
$-48.0M
$-8.0M
Q1 25
$-59.4M
$2.0M
Q4 24
$-74.9M
Q3 24
$-64.6M
$-204.9M
Q2 24
$-79.3M
Q1 24
$-68.4M
Gross Margin
AXSM
AXSM
SMC
SMC
Q4 25
72.1%
Q3 25
74.0%
Q2 25
74.4%
Q1 25
73.3%
Q4 24
Q3 24
72.4%
Q2 24
Q1 24
Operating Margin
AXSM
AXSM
SMC
SMC
Q4 25
-13.8%
-5.5%
Q3 25
-27.0%
3.8%
Q2 25
-24.5%
-3.6%
Q1 25
-46.9%
3.7%
Q4 24
-61.1%
Q3 24
-59.8%
-53.7%
Q2 24
-89.5%
Q1 24
-89.7%
Net Margin
AXSM
AXSM
SMC
SMC
Q4 25
-14.6%
-5.1%
Q3 25
-27.6%
-1.1%
Q2 25
-32.0%
-5.7%
Q1 25
-48.9%
1.5%
Q4 24
-63.1%
Q3 24
-61.7%
-200.1%
Q2 24
-91.0%
Q1 24
-91.1%
EPS (diluted)
AXSM
AXSM
SMC
SMC
Q4 25
$-0.55
$-0.66
Q3 25
$-0.94
$-0.13
Q2 25
$-0.97
$-0.66
Q1 25
$-1.22
$-0.16
Q4 24
$-1.54
Q3 24
$-1.34
$-19.25
Q2 24
$-1.67
Q1 24
$-1.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
SMC
SMC
Cash + ST InvestmentsLiquidity on hand
$322.9M
$9.3M
Total DebtLower is stronger
$1.0B
Stockholders' EquityBook value
$88.3M
$546.2M
Total Assets
$689.8M
$2.4B
Debt / EquityLower = less leverage
1.91×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
SMC
SMC
Q4 25
$322.9M
$9.3M
Q3 25
$325.3M
$24.6M
Q2 25
$303.0M
$20.9M
Q1 25
$300.9M
$26.2M
Q4 24
$315.4M
Q3 24
$327.3M
$17.8M
Q2 24
$315.7M
Q1 24
$331.4M
Total Debt
AXSM
AXSM
SMC
SMC
Q4 25
$1.0B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
Q3 24
$957.0M
Q2 24
Q1 24
Stockholders' Equity
AXSM
AXSM
SMC
SMC
Q4 25
$88.3M
$546.2M
Q3 25
$73.7M
$551.9M
Q2 25
$73.1M
$552.0M
Q1 25
$53.2M
$558.1M
Q4 24
$57.0M
Q3 24
$92.9M
$651.5M
Q2 24
$102.9M
Q1 24
$144.0M
Total Assets
AXSM
AXSM
SMC
SMC
Q4 25
$689.8M
$2.4B
Q3 25
$669.3M
$2.4B
Q2 25
$639.8M
$2.4B
Q1 25
$596.7M
$2.4B
Q4 24
$568.5M
Q3 24
$561.5M
$2.0B
Q2 24
$548.2M
Q1 24
$545.7M
Debt / Equity
AXSM
AXSM
SMC
SMC
Q4 25
1.91×
Q3 25
1.96×
Q2 25
1.95×
Q1 25
1.94×
Q4 24
Q3 24
1.47×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
SMC
SMC
Operating Cash FlowLast quarter
$-18.7M
$53.7M
Free Cash FlowOCF − Capex
$-18.7M
$34.5M
FCF MarginFCF / Revenue
-9.6%
24.3%
Capex IntensityCapex / Revenue
0.0%
13.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$44.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
SMC
SMC
Q4 25
$-18.7M
$53.7M
Q3 25
$1.0M
$26.7M
Q2 25
$-32.4M
$37.2M
Q1 25
$-43.4M
$16.0M
Q4 24
$-26.2M
Q3 24
$-18.6M
Q2 24
$-30.1M
Q1 24
$-53.5M
Free Cash Flow
AXSM
AXSM
SMC
SMC
Q4 25
$-18.7M
$34.5M
Q3 25
$988.0K
$3.8M
Q2 25
$-32.4M
$10.8M
Q1 25
$-43.7M
$-4.6M
Q4 24
$-26.2M
Q3 24
$-18.7M
Q2 24
$-30.2M
Q1 24
$-53.6M
FCF Margin
AXSM
AXSM
SMC
SMC
Q4 25
-9.6%
24.3%
Q3 25
0.6%
2.6%
Q2 25
-21.6%
7.7%
Q1 25
-36.0%
-3.4%
Q4 24
-22.1%
Q3 24
-17.9%
Q2 24
-34.6%
Q1 24
-71.4%
Capex Intensity
AXSM
AXSM
SMC
SMC
Q4 25
0.0%
13.4%
Q3 25
0.0%
15.6%
Q2 25
0.0%
18.8%
Q1 25
0.3%
15.5%
Q4 24
0.0%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
AXSM
AXSM
SMC
SMC
Q4 25
Q3 25
Q2 25
Q1 25
7.89×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

SMC
SMC

Rockies Segment$86.2M61%
Mid Con Barnett Shale Segment$39.4M28%
Piceance Basin Segment$15.8M11%

Related Comparisons